Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

3 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Placebo

Core clinician-reference fields are available or not applicable.

Participants receiving liraglutide in the LEADER trial.

Liraglutide

Individual-level data consisting of 9340 (liraglutide: 4668; placebo: 4672) and 3297 (semaglutide: 1648; placebo: 1649) subjects from the LEADER and SUSTAIN-6 trials, respectively, was utilized for this study.

Participants receiving semaglutide in the SUSTAIN-6 trial.

Semaglutide

Participants receiving placebo in the LEADER trial.

Participants receiving placebo in the SUSTAIN-6 trial.

HbA1c mediates cardiovascular benefits of GLP-1 receptor agonists

Available source content was suppressed because validation identified a conflict.

Participants receiving semaglutide in the SUSTAIN 6 trial.

Individual participant data from participants in the SUSTAIN 6 (N = 3297) and PIONEER 6 (N = 3183) CVOTs, receiving semaglutide (SUSTAIN 6: OW s.c. 0.5 or 1.0 mg; PIONEER 6: OD oral 14 mg) or placebo, were used in this analysis.

Participants receiving placebo in the SUSTAIN 6 and PIONEER 6 trials.

Data from the s.c. and oral semaglutide arms were pooled and compared with pooled placebo data from both trials.

Authoritative quality diagnostic: invalid or missing unit.

Semaglutide improves cardiorenal outcomes in high-risk diabetes patients

Participants received semaglutide to evaluate cardiovascular, metabolic, and safety outcomes.

In SUSTAIN 6, participants received OW s.c. semaglutide 0.5 mg or 1.0 mg (median follow-up of 2 years), while in PIONEER 6, participants received OD oral semaglutide 14 mg (median observation time of 15.9 months).

Participants received a dose-matched placebo as a comparator to semaglutide.

In both trials, the comparator was dose-matched placebo and treatments were in addition to standard of care.

Semaglutide reduces cardiovascular events and body weight in T2D

Structured population data were available for 7 of 7 supporting studies. 6 studies described participants with type 2 diabetes. 7 studies described adult participants.

4 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: placebo, usual_care.

1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Structured population data were available for 4 of 4 supporting studies. 3 studies described participants with type 2 diabetes. 4 studies described adult participants.

Upstream consistency scoring indicates mixed findings across the evidence.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 3 of 3 supporting studies. 1 study described participants with type 2 diabetes. 3 studies described adult participants.

2 of 3 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 6 of 6 supporting studies. 4 studies described participants with type 2 diabetes. 6 studies described adult participants.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

Semaglutide × Cardiovascular death

Available supporting studies

HbA1c mediates cardiovascular benefits of GLP-1 receptor agonists

Semaglutide improves cardiorenal outcomes in high-risk diabetes patients

Semaglutide reduces cardiovascular events and body weight in T2D